Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • GD2IL18CARTRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: INFUSION

    View study and source
  • GD2IL18CARTRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: INFUSION

    View study and source

Success Metrics

Active Trials
2(100%)

Phase Distribution

Phase 1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
recruitingphase_1

Long-term follow-up of patients treated with GD2IL18CART

SYF5355abaca1cc441b92a5ee4afd6c02ce
recruitingphase_1

A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers

SYFb9f4a45a0eb342e8be6c1446d44126b8

Clinical Trials (2)

Showing 2 of 2 trials
SYF5355abaca1cc441b92a5ee4afd6c02cePhase 1

Long-term follow-up of patients treated with GD2IL18CART

Recruiting
SYFb9f4a45a0eb342e8be6c1446d44126b8Phase 1

A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
Type not reported
Total Trials
2